Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLASSIA for Acute GvHD with Lower GI Involvement
NCT02956122Phase 3Terminated
- Sponsor
- Takeda
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha-1-proteinase inhibitor in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Takeda. Primary endpoint: Overall Response Rate at 28 days. Started Apr 2017; status: terminated.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02956122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956122.